Formulation and Characterization of Bilayer Tablet of Anti-hyperlipidemic BCS Class II drug

Authors

  • Supriya S. Bhagwat
  • Poonam P. Patil
  • Sunil J. Aher
  • Mohsina Patwekar
  • Faheem Patwekar

DOI:

https://doi.org/10.37591/(rrjops).v14i1.1261

Abstract

The main objective of work was to formulate co-loaded bilayer tablets of atorvastatin (ATV) and ezetimibe(EZM).ATV loaded in the immediate-release (IR) layer is an HMG CoA reductase inhibitor, while EZM, added in the immediate-release (IR)  layer, is a lipid-lowering agent. The immediate release of BCS class II drugs atorvastatin and Ezetimibe, in a bilayer approach was achieved by  wet granulation and fluid bed granulation  followed by compression. The Preformulation studies like, bulk density, tapped density, moisture content, forced degradation study and compatibility of API with all excipients were carried out. The dissolution study of optimize formula were carried out using pH 6.8 phosphate buffer + 0.2%w/v tween 80. Coating was done with opadry white (non-functional coating).

The main objective of work was to formulate co-loaded bilayer tablets of atorvastatin (ATV) and ezetimibe(EZM).ATV loaded in the immediate-release (IR) layer is an HMG CoA reductase inhibitor, while EZM, added in the immediate-release (IR)  layer, is a lipid-lowering agent. The immediate release of BCS class II drugs atorvastatin and Ezetimibe, in a bilayer approach was achieved by  wet granulation and fluid bed granulation  followed by compression. The Preformulation studies like, bulk density, tapped density, moisture content, forced degradation study and compatibility of API with all excipients were carried out. The dissolution study of optimize formula were carried out using pH 6.8 phosphate buffer + 0.2%w/v tween 80. Coating was done with opadry white (non-functional coating).

Downloads

Published

2023-05-20

Issue

Vol. 14 No. 1 (2023)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.